Cited 41 times in
A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 금웅섭 | - |
dc.date.accessioned | 2015-04-24T17:33:37Z | - |
dc.date.available | 2015-04-24T17:33:37Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0360-3016 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/105631 | - |
dc.description.abstract | PURPOSE: We evaluated the efficacy of synchronous three-dimensional (3D) conformal boost to the gross tumor volume (GTV) in concurrent chemoradiotherapy for patients with locally advanced non-small-cell lung cancer (NSCLC). METHODS AND MATERIALS: Eligibility included unresectable Stage III NSCLC with no pleural effusion, no supraclavicular nodal metastases, and Eastern Cooperative Oncology Group performance score of 0-1. Forty-nine patients with pathologically proven NSCLC were enrolled. Eighteen patients had Stage IIIA and 31 had Stage IIIB. By using 3D conformal radiotherapy (RT) techniques, a dose of 1.8 Gy was delivered to the planning target volume with a synchronous boost of 0.6 Gy to the GTV, with a total dose of 60 Gy to the GTV and 45 Gy to the planning target volume in 25 fractions during 5 weeks. All patients received weekly chemotherapy consisting of paclitaxel and carboplatin during RT. RESULTS: With a median follow-up of 36.8 months (range, 29.0-45.5 months) for surviving patients, median survival was 28.1 months. One-, 2- and 3-year overall survival rates were 77%, 56.4%, and 43.8%, respectively. Corresponding local progression-free survival rates were 71.2%, 53.7%, and 53.7%. Compliance was 90% for RT and 88% for chemotherapy. Acute esophagitis of Grade 2 or higher occurred in 29 patients. Two patients with T4 lesions died of massive bleeding and hemoptysis during treatment (Grade 5). Overall late toxicity was acceptable. CONCLUSIONS: Based on the favorable outcome with acceptable toxicity, the acceleration scheme using 3D conformal GTV boost in this trial is warranted to compare with conventional fractionation in a Phase III trial. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1397~1404 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use | - |
dc.subject.MESH | Carboplatin/administration & dosage | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/drug therapy | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/mortality | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/pathology | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/radiotherapy* | - |
dc.subject.MESH | Combined Modality Therapy/methods | - |
dc.subject.MESH | Dose Fractionation | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Korea | - |
dc.subject.MESH | Lung Neoplasms/drug therapy | - |
dc.subject.MESH | Lung Neoplasms/mortality | - |
dc.subject.MESH | Lung Neoplasms/pathology | - |
dc.subject.MESH | Lung Neoplasms/radiotherapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Paclitaxel/administration & dosage | - |
dc.subject.MESH | Radiotherapy, Conformal/methods* | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Treatment Failure | - |
dc.subject.MESH | Tumor Burden | - |
dc.title | A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학) | - |
dc.contributor.googleauthor | KWAN HO CHO | - |
dc.contributor.googleauthor | SUNG JA AHN | - |
dc.contributor.googleauthor | HONG RYULL PYO | - |
dc.contributor.googleauthor | KYU-SIK KIM | - |
dc.contributor.googleauthor | YOUNGCHUL KIM | - |
dc.contributor.googleauthor | SUNG HO MOON | - |
dc.contributor.googleauthor | JI-YOUN HAN | - |
dc.contributor.googleauthor | HEUNG TAE KIM | - |
dc.contributor.googleauthor | WOONG SUB KOOM | - |
dc.contributor.googleauthor | JIN SOO LEE | - |
dc.identifier.doi | 10.1016/j.ijrobp.2008.10.020 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00273 | - |
dc.relation.journalcode | J01157 | - |
dc.identifier.eissn | 1879-355X | - |
dc.identifier.pmid | 19117690 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0360301608036523 | - |
dc.contributor.alternativeName | Koom, Woong Sub | - |
dc.contributor.affiliatedAuthor | Koom, Woong Sub | - |
dc.citation.volume | 74 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1397 | - |
dc.citation.endPage | 1404 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.74(5) : 1397-1404, 2009 | - |
dc.identifier.rimsid | 40929 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.